

CORPORATE PROFILE

Novo Nordisk A/S

1. Head office:

Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd
Denmark

Tel: +45 44 44 88 88

Fax: +45 44 49 05 55

2. Management:

Mr Mads Øvlisen, President and CEO
Mr Kurt Stenager, Director, Health Care Group
Mr Steen Riisgaard, Director, Bioindustrial Group
Mr Ulrik V. Lassen, Director, Corporate R&D
Mr Knud Austrup, Director of Research, Industrial Biotechnology

3: Indicators (1990)

Annual sales: CAD 1,800 Million
R & D expenses: CAD 270 Million
Employees: 10,200
R & D Employees: 1,900

4. Principal Activities:

Novo Nordisk A/S is a world leading biotechnology corporation with production of insulin, other pharmaceutical products, industrial enzymes, bio pesticides and other bioindustrial products as the principal activities. It is a major force in insulin manufacture and diabetes treatment and is the world's largest producer of industrial enzymes.

5. History:

The corporation was founded in 1989 as a merger between the two Danish companies Novo Industri A/S (1925) and Nordisk Gentofte A/S (1923).

Biotechnology activities

Research & Development:

- * Insulin and diabetes care
- * Growth regulators and blood products
- * CNS-products
- * Industrial enzymes
- * Biopesticides